Oculis Holding AG (CR5.F)
| Previous close | 11.10 |
| Open | 11.80 |
| Bid | 12.10 x N/A |
| Ask | 12.30 x N/A |
| Day's range | 11.80 - 12.10 |
| 52-week range | 8.50 - 12.80 |
| Volume | |
| Avg. volume | 3 |
| Market cap | 506.076M |
| Beta (5Y monthly) | 0.18 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
Oculis Publishes Invitation to the Annual General Meeting
ZUG, Switzerland, April 29, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq Global Market: OCS) (“Oculis”), today published the invitation to the 2024 Annual General Meeting, which will be held on 29 May 2024 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:30 p.m. CEST / 9:30 a.m. EDT. All information pertaining to the 2024 Annual General Meeting, including meeting materials, can be accessed on the Oculis website at https://investors.oculis.com/events-presentations. About Oculis
- GlobeNewswire
Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market
Raised gross proceeds of $59 million through the issuance and sale of 5,000,000 of its ordinary shares to Icelandic institutional and existing investorsBecomes second company dual-listed on NASDAQ U.S. and NASDAQ Iceland Main Market, trading under the symbol “OCS” beginning April 23, 2024Oculis will ring the Nasdaq Iceland opening bell on April 23, 2024, at 9:30 GMTPhase 2b RELIEF trial of OCS-02 (Licaminlimab) in Dry Eye Disease (DED) remains on track to readout in Q2 2024 ZUG, Switzerland, Apr
- Globe Newswire
Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market
$59 million financing includes participation from new Icelandic institutional and existing investors; Extends cash runway until 2H 2026 The Central Bank of Iceland, Financial Supervision has approved Oculis’s prospectus related to the admission of its ordinary shares to trade on the Nasdaq Iceland Main Market; Oculis will announce the first day of trading with at least one day advance noticeOn-track to report topline data from OCS-02 (licaminlimab) Phase 2b RELIEF trial in Dry Eye Disease (DED)
